港股新股劲方医药涨近120%

Group 1 - The core point of the article is that Jinfang Pharmaceutical-B (02595.HK) has seen a significant increase in its stock price, rising nearly 120% as of the report date [1] - During the public offering phase, Jinfang Pharmaceutical-B received a subscription rate of 2,662.79 times, indicating strong investor interest [1] - In the international placement phase, the subscription rate was 39.05 times, further demonstrating robust demand for the company's shares [1]